Management of Chronic Fatigue Syndrome in Children

References

• Bell DS. Chronic fatigue syndrome in children. Journ Chtvn Fatigue Syndr 1995; 1(1): 9–33.
   Google Scholar
• Lapp CW, Cheney PR, Ouyang G. Specialist evaluation in Chronic fatigue syndrome: a cost/benefit analysis, presented to the International Meeting on Chronic Fatigue Syndrome, Dublin, Ireland, May 1994.
   Google Scholar
• Lapp CW, Cheney PR. The rationale for using high dose cobalamin. The CFIDS Chronicle, Fall 1993:19–21.
   Google Scholar
• Buchwald D, Goldenberg DL et al. The chronic active epstein-barr virus infection syndrome and primary fibromyalgia. Arthritis and Rheumatism 1987; 30:1132–1136.
   PubMed Web of Science ®Google Scholar
• McCain GA, Bell DA, Mai F, Halliday PD. A controlled study of the effec-tiveness of the effects of a supervised cardiovascular fitness training program on the manifestations of the primary fibromyalgia syndrome. Arthritis Rheum 1988; 31(9):1135–1141.
   PubMed Web of Science ®Google Scholar
• Sisto SA. Rehabilitation of the patient with CFS. Journ Citron Fatigue Syndr 1995; 1(3/4): 100–104.
   Google Scholar
• Wilke WS. Treatment of "resistant" fibromyalgia. Rheum Dis Clin North Am 1995; 21(1):247–260.
   PubMed Web of Science ®Google Scholar
• Carette S, McCain GA et al. Evaluation of amitriptyline in primary fibrosi-tis. Arthritis Rheum 1985; 29:655–659.
   Google Scholar
• Scudds RA, McCain GA et al. Improvements in pain responsiveness in pa-tients with fibrositis after successful treatment with amitriptyline. J Rheumatol 1989;16(Suppl 19):113–119.
   PubMedGoogle Scholar
• Goldenberg DL, Felson DI, Dinerman H. A randomized controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthri-tis Rheum 1986;29:1371–1377.
   Google Scholar
• Jaeschke R, Adachi .1 et al. Clinical usefulness of amitriptyline in fibromy-algia. J Rheum/do/ 1991; 18: 447–451.
   Google Scholar
• Carette S, Bell MJ et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. Arthritis Rheum 1994; 37:32–40.
   PubMed Web of Science ®Google Scholar
• Reynolds WJ, Moldofsky H et al. The effects of cyclobenzaprine on sleep physiology and symptoms in fibromyalgia; J Rheumatol 1991;18:452–454.
   Google Scholar
• Bennett RM, Gatter RA et al. A comparison of cyclobenzaprine and place-bo in the management of fibrositis. Arthritis Rheumat 1988; 31(12):1535–1542.
   PubMed Web of Science ®Google Scholar
• Quimby LG, Gratwick GM et al. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol 1989;16(Suppl 19):140–143.
   Google Scholar
• Russell 1.1, Fletcher EM et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. Arthritis Rheum 1991; 34: 552–560.
   Google Scholar
• Russell IJ, Michalek JE et al. Platelet 3-H-imipramine uptake receptor density and serotonin levels in patients with fibromyalgi a/fibrositis syndrome. J Rheumtol 1992; 19:104–109.
   PubMed Web of Science ®Google Scholar
• Klimas NG, Morgan R, VanRiel F, Fletcher MA. Observations regarding the use of an antidepressant, fluoxetine, in chronic fatigue syndrome. In Goodnick PJ, Klimas NO (eds), Chronic fatigue and related immune deficiency syndromes. American Psychiatric Press, Washington DC, 1993:95–108.
   Google Scholar
• Behan PO, Hannifah BAG et al. A pilot study of sertraline for the treatment of chronic fatigue syndrome. Clin Inf Dis 1994; 18(Suppl 1): S111.
   Google Scholar
• Goodnick PJ, Sandoval R, Brickamn A, Klimas NO. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry 1992;32(9): 834–838.
   PubMed Web of Science ®Google Scholar
• Bruno RL, Frick NM, Creange S et al. Polioencephalitis and the brain fa-tigue generator model of post-viral fatigue syndromes. Journ Chronic Fatigue Synd 1996; 3:5–27.
   Google Scholar
• Lapp CW, Preston MA, Cheney PR. An evolving diagnostic marker for chronic fatigue immune dysfunction syndrome using EEG technology, presented before the 1994 AACFS Scientific and Research Conference, Fort Lauderdale.
   Google Scholar
• Rowe P, Bou-Holaigah I, Kan JS, Calkins H. Is neurally mediated hypoten-sion an unrecognized cause of chronic fatigue? Lancet 1995; 345: 623–624.
   PubMed Web of Science ®Google Scholar
• Bou-Holaigah I, Rowe P, Kan JS, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995; 274(12):961–967.
   Google Scholar
• Jones JF, Chronic Epstein-Barr virus syndrome. Bull NY Acad Med 1988; 64:538–543,
   PubMedGoogle Scholar
• Straus SE, Dale JK et al. Acyclovir treatment of the chronic fatigue syn-drome: lack of efficacy in a placebo-controlled trial. NEJM 1988; 319: 1692–1698.
   PubMed Web of Science ®Google Scholar
• Steinbach T, Hermann W, Lawyer C, Montefiore D et al. Subjective reduc-tion in symptoms of chronic fatigue syndrome following long term treatment with a porcine liver extract. Clin Infect Dis 1994; 18(Suppl I): S114.
   Google Scholar
• Strayer DR, Carter W et al. Long term improvement in patients with chron-ic fatigue syndrome treated with Ampligen. Journ Chronic Fatigue Syndr 1995; 1:35–53.
   Google Scholar
• DeMeirleir K. A review of the use of antiviral and immunomodulating drugs in the treatment of chronic fatigue syndrome. form; Chronic Fatigue Synch-1996; 2(2/3):127.
   Google Scholar
• Klimas NO, Salvato FR, Morgan R, Fletcher MA. Immunological abnor-malities in chronic fatigue syndrome. Journ Clinical Microbiol 1990; 28(6): 1403–1410.
   PubMed Web of Science ®Google Scholar
• Komarofr AL, Geiger NM, Wormescly S. IgG subclass deficiencies in chronic fatigue syndrome. Lancet 1988; 1;1288–1289.
   Google Scholar
• Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991; 338(8769): 707–712.
   PubMed Web of Science ®Google Scholar
• Peterson PK, Shephard .1 et al. A controlled trial of intravenous immuno-globulin Gin chronic fatigue syndrome. Ant J Med 1990; 89:554–560.
   Google Scholar
• Lloyd AR, Hickie I et al. A double blind, placebo-controlled trial of intra-venous immunoglobulin therapy in patients with chronic fatigue syndrome. An; J Med 1990; 89:561–568.
   PubMed Web of Science ®Google Scholar
• Wilson A, Hickie I, Lloyd A et al. Longitudinal study of chronic fatigue syndrome. Br Med J 1994; 308:756–759.
   PubMed Web of Science ®Google Scholar
• DuBois RE. Gamma globulin therapy for chronic mononucleosis syn-drome. AIDS Res 1986; 2(Suppl I ):S191–S195.
   Google Scholar
• Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet 1991; 337:757–760.
   Google Scholar
• Demilrack MA, Dale JK, Straus SE et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syn-drome. Chu Endoermol Metab 1991; 73:1224–1230.
   PubMed Web of Science ®Google Scholar
• Behan PO and Behan WMH. Post viral fatigue syndrome, CRC Critical Reviews in Neurobiology 1988; 4:157–178.
   PubMed Web of Science ®Google Scholar
• Sharpe MC. Cognitive-Behavioral Therapy for Patients with Chronic Fa-tigue Syndrome: How? in Demitrack M and Abbey SE (eds): Chronic Fatigue Syndrome: An Integrative Approach to Evaluation and Meatment. New York: Guilford Press, 1996: 240–262.
   Google Scholar